Novo Integrated Sciences AI Stock Analysis
Want to see NVOS full AI Analyst Report?
Novo Integrated Sciences (NVOS) AI Stock Analysis
Novo Integrated Sciences
(Other OTC:NVOS)
The overall score is driven by extraordinarily weak financial performance and valuation: persistent operating and net losses, worsening negative cash flow, and no dividend or earnings support the lowest possible assessment. Technical analysis is also scored at the minimum due to the lack of positive indicators and a very low share price, reflecting high investor caution and likely negative sentiment. With no offsetting positives or external events, the score reflects acute risk and minimal investor confidence.
Novo Integrated Sciences (NVOS) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- $17.76K
- Dividend Yield
- ―
- Average Volume (3M)
- ―
- Price to Earnings (P/E)
- 0.0
- Beta (1Y)
- 3.55
- Revenue Growth
- ―
- EPS Growth
- ―
- Country
- US
- Employees
- 115
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Medical - Care Facilities
Novo Integrated Sciences Business Overview & Revenue Model
Company Description
Novo Integrated Sciences, Inc. (NVOS) delivers a diverse array of primary healthcare services and related products through its two primary operational segments: Healthcare Services and Product Manufacturing and Development. The company's extensive se...
How the Company Makes Money
Novo Integrated Sciences generates revenue through several key streams, including the sale of its proprietary health and wellness products, licensing agreements for its technology and products, and partnerships with healthcare providers and distribut...
Novo Integrated Sciences Financial Statement Overview
Summary
Novo Integrated Sciences demonstrates severe financial weakness: persistent operating and net losses (net margin at -121.3%, EBIT and EBITDA at -75.8%), worsening negative free cash flow (-$2.3M with no year-over-year improvement), and a deteriorating equity base. While revenue grew modestly and leverage is only moderately high, these positives are overshadowed by chronic unprofitability and cash burn, raising major concerns about sustainability.
Income Statement
18Very NegativeBalance Sheet
25NegativeCash Flow
11Very Negative| Breakdown | TTM | Aug 2024 | Nov 2023 | Feb 2023 | Nov 2021 | Aug 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 13.29M | 13.29M | 12.57M | 11.74M | 9.31M | 7.86M |
| Gross Profit | 5.74M | 5.74M | 4.95M | 4.80M | 3.82M | 3.06M |
| EBITDA | -6.64M | -14.52M | -5.85M | -22.48M | -2.58M | -3.32M |
| Net Income | -16.17M | -16.13M | -13.21M | -32.85M | -4.46M | -4.92M |
Balance Sheet | ||||||
| Total Assets | 32.14M | 32.14M | 35.56M | 40.87M | 61.96M | 35.39M |
| Cash, Cash Equivalents and Short-Term Investments | 844.58K | 844.58K | 416.32K | 2.18M | 8.29M | 2.07M |
| Total Debt | 4.71M | 4.71M | 4.47M | 13.00M | 13.71M | 4.39M |
| Total Liabilities | 17.53M | 17.53M | 11.06M | 18.83M | 18.15M | 5.82M |
| Stockholders Equity | 14.89M | 14.89M | 24.82M | 22.31M | 43.86M | 29.62M |
Cash Flow | ||||||
| Free Cash Flow | -5.07M | -2.29M | -2.29M | -6.07M | -1.28M | -453.80K |
| Operating Cash Flow | -5.07M | -2.24M | -2.24M | -5.88M | -1.02M | -441.69K |
| Investing Cash Flow | -5,033 | -49.22K | -49.22K | 163.46K | 3.00M | 657.13K |
| Financing Cash Flow | 4.99M | 763.86K | 763.86K | -427.12K | 4.32M | -271.69K |
Novo Integrated Sciences Risk Analysis
Novo Integrated Sciences disclosed 16 risk factors in its most recent earnings report. Novo Integrated Sciences reported the most risks in the "Ability to Sell" category.
Latest Risks Added
0 New RisksNovo Integrated Sciences Peers Comparison
Overall Rating
CCEL53Neutral
AMS50Neutral
PIII48Neutral
MNDR43Neutral
CCM40Underperform
NVOS37Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| 53Neutral | $33.62M | -18.60 | 15.84% | ― | -1.96% | -314.41% | |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| 50Neutral | $6.88M | -3.03 | -10.19% | ― | 4.90% | -3.41% | |
| 48Neutral | $15.61M | -0.09 | 171.75% | ― | 7.54% | 42.43% | |
| 43Neutral | $1.13M | -0.04 | -27.32% | ― | 4.47% | 92.03% | |
| 40Underperform | $15.67M | -0.03 | 5.16% | ― | 20.26% | 69.68% | |
| 37Underperform | $17.76K | 0.00 | -81.23% | ― | ― | ― |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| NVOS | Novo Integrated Sciences, Inc. | 0.02 | -0.01 | -33.33% | |
| AMS | American Shared Hospital Services | 1.03 | -1.04 | -50.24% | |
| CCM | Concord Medical Services | 3.61 | 0.01 | 0.28% | |
| CCEL | Cryo-Cell International | 4.17 | 0.08 | 1.91% | |
| PIII | P3 Health Partners Inc. | 2.15 | -3.56 | -62.35% | |
| MNDR | Mobile-health Network Solutions Class A | 0.95 | -27.55 | -96.67% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Jul 23, 2025
